The rest of the 100 (in alphabetical order): Lutz Stoeber, Evonik Venture Capital
After celebrating his success as a GCV Rising Star in 2017, Lutz Stoeber, investment director at Evonik Venture Capital, Germany-based speciality chemicals producer Evonik Industries’ corporate venture capital arm, has been chosen again for stardom.
Stoeber joined the unit when it was formed in 2012 as one of the founding members and an investment manager, before being promoted to his current position a year later. His current responsibility is to identify and invest in companies with strategic relevance to Evonik, including innovative technologies with high growth potential in the field of advanced materials, sustainable nutrition, advanced food ingredients, additive manufacturing, personal care and healthcare, mainly in North America.
Evonik Venture Capital’s first fund is a €100m ($113m) early-stage and growth capital fund that has invested in 25 companies and venture funds to date. Recently, it has expanded its corporate venturing activities into Asia with two fund investments in China.
Stoeber said: “We take board seats and shareholder representative roles in our portfolio companies and advisory board seats in our fund investments. I am actively engaged with the following portfolio companies – Pangaea Ventures Fund III, mySkin, Wiivv Wearables, Algal Scientific, NIS and Vivasure.”
Bernhard Mohr, managing director at Evonik Venture Capital, nominating Stoeber, said: “Lutz was a founding member of our venture capital group that started in 2012. When setting up Evonik Venture Capital, Lutz was instrumental in establishing processes and his extensive transactional experience helped build a team of now seasoned investment professionals.
